A Phase 3, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with Intermediate or High Risk Non-muscle Invasive Bladder Cancer (NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)